Search research articles
Contact Us
Filters
Showing results (31-40 of 331) with videos related to
Page
of 34
Sort By:
European Urology
|
December 3, 2015
Comparing Everolimus to Sunitinib in Non-clear-cell Renal Cell Carcinoma
Axel Bex, Börje Ljungberg
European Urology Oncology
|
December 4, 2025
Assessment of Pathologic Response in Kidney Cancer: Back to the Microscope for Now
Axel Bex, Grant D Stewart
Current Oncology Reports
|
February 8, 2011
Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalities
Axel Bex, James Larkin, Christian Blank
Cardiovascular and Interventional Radiology
|
October 21, 2011
Percutaneous radiofrequency ablation of a small renal mass complicated by appendiceal perforation
Judith Boone, Axel Bex, Warner Prevoo
The New England Journal of Medicine
|
November 9, 2018
Sunitinib Alone or after Nephrectomy in Renal Cancer
Axel Bex, Thomas Powles, John Haanen
European Urology
|
March 30, 2019
Re: Paul C.M.S. Verhagen, Egbert R. Boevé. The European Association of Urology Guideline on Renal Cell Carcinoma (RCC) is Not Concise in its Recommendation to Perform Partial Nephrectomy in T1b RCC. Eur Urol 2019:76:136-7
Lorenzo Marconi, Karim Bensalah, Axel Bex, et al.
Current Opinion in Urology
|
July 30, 2016
Metastasis therapies for renal cancer
Saeed Dabestani, Lorenzo Marconi, Axel Bex
Urology
|
September 5, 2017
Author Reply
Roderick E de Bruijn, Axel Bex
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 21, 2015
Challenging the treatment paradigm for advanced renal cell carcinoma: a review of systemic and localized therapies
Axel Bex, James Larkin, Martin Voss
Current Opinion in Urology
|
March 26, 2021
Editorial: Standard and future in the treatment of renal cell carcinoma
Jens Bedke, Axel Bex, Manuela Schmidinger
Page
of 34
Search research articles
Search
Showing results (31-40 of 331) with videos related to
Sort By:
Page
of 34
European Urology
|
December 3, 2015
Comparing Everolimus to Sunitinib in Non-clear-cell Renal Cell Carcinoma
Axel Bex, Börje Ljungberg
European Urology Oncology
|
December 4, 2025
Assessment of Pathologic Response in Kidney Cancer: Back to the Microscope for Now
Axel Bex, Grant D Stewart
Current Oncology Reports
|
February 8, 2011
Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalities
Axel Bex, James Larkin, Christian Blank
Cardiovascular and Interventional Radiology
|
October 21, 2011
Percutaneous radiofrequency ablation of a small renal mass complicated by appendiceal perforation
Judith Boone, Axel Bex, Warner Prevoo
The New England Journal of Medicine
|
November 9, 2018
Sunitinib Alone or after Nephrectomy in Renal Cancer
Axel Bex, Thomas Powles, John Haanen
European Urology
|
March 30, 2019
Re: Paul C.M.S. Verhagen, Egbert R. Boevé. The European Association of Urology Guideline on Renal Cell Carcinoma (RCC) is Not Concise in its Recommendation to Perform Partial Nephrectomy in T1b RCC. Eur Urol 2019:76:136-7
Lorenzo Marconi, Karim Bensalah, Axel Bex, et al.
Current Opinion in Urology
|
July 30, 2016
Metastasis therapies for renal cancer
Saeed Dabestani, Lorenzo Marconi, Axel Bex
Urology
|
September 5, 2017
Author Reply
Roderick E de Bruijn, Axel Bex
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 21, 2015
Challenging the treatment paradigm for advanced renal cell carcinoma: a review of systemic and localized therapies
Axel Bex, James Larkin, Martin Voss
Current Opinion in Urology
|
March 26, 2021
Editorial: Standard and future in the treatment of renal cell carcinoma
Jens Bedke, Axel Bex, Manuela Schmidinger
Page
of 34